NCT02859090

Brief Summary

It has recently been shown that various HSPs are strongly expressed in B lymphomas. Indeed, HSP90 stabilizes the protein Bcl-6 in diffuse large-cell B lymphomas. Pharmacological inhibition of HSP90 in vitro induced apoptosis in lymphoma cells (Cerchietti et al. Nat. Medicine, 2009, 1369-1376). In addition, HSP110 is strongly expressed in non-Hodgkin lymphomas, and targeting this HSP at the cell surface using specific antibodies could constitute a future therapy (Zappasodi et al. Blood, 2011, 4421-4430). Despite the importance of these proteins in the development of lymphomas, their expression and their role in the activation of normal B lymphocytes and the normal development of germinal centres is not known. The expression of Heat shock proteins should vary among the different B lymphocyte populations present in the tonsils (naïve B cells, memory B cells, germinal centre B cells). The aim of this study is to establish an expression profile for heat shock proteins in populations of B lymphocytes in human tonsils

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 26, 2014

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 20, 2014

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

August 4, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 8, 2016

Completed
Last Updated

January 10, 2019

Status Verified

January 1, 2019

Enrollment Period

3 months

First QC Date

August 4, 2016

Last Update Submit

January 9, 2019

Conditions

Tonsillectomy

Outcome Measures

Primary Outcomes (1)

  • expression of heat shock proteins

    Day one

Study Arms (1)

patient

EXPERIMENTAL
Procedure: tonsillectomyBiological: blood sample

Interventions

tonsillectomyPROCEDURE
patient
blood sampleBIOLOGICAL
patient

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Persons who have provided oral consent
  • Tonsillectomy in children or adults

You may not qualify if:

  • Persons without national health insurance cover
  • Adults under guardianship
  • Pregnant or breast-feeding women
  • Persons with positive HIV or HCV serology

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Dijon Bourgogne

Dijon, 21079, France

Location

MeSH Terms

Interventions

TonsillectomyBlood Specimen Collection

Intervention Hierarchy (Ancestors)

Otorhinolaryngologic Surgical ProceduresSurgical Procedures, OperativeSpecimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 4, 2016

First Posted

August 8, 2016

Study Start

August 26, 2014

Primary Completion

November 20, 2014

Study Completion

November 20, 2014

Last Updated

January 10, 2019

Record last verified: 2019-01

Locations

FR(1)